Page 15 - Accomplishments Dr. Sinnott and Dr. Oxner Revised Table_Classical
P. 15

RESEARCH
                                                                    Approved Active Studies

                   •  Drug: Emergency use, Remdesivir -  For the Treatment of Selected Coronavirus (CoV) Infection
                   •  Device: 3D Swabs
                   •  Regeneron – Assessing Efficacy and Safety of Sarilumab for Hospitalized Patients with COVID-19
                   •  Expanded Access to Convalescent Plasma for the Treatment of Patients with COVID-19
                   •  Drug: Hydroxychloroquine for SARS-CoV - The purpose of this study is to assess the benefits to health outcomes of administering
                       hydroxychloroquine vs. placebo in outpatients with confirmed SARS-CoV-2.

                                                                           Pending Approval
                   •  HERO registry – Purpose: Health care workers registry
                   •  Drug: PCORI-Prophy for HCW – Purpose:  Prophylactic effect drug treatment for healthcare workers
                   •  National Registry for Surveillance and Epidemiology of Perinatal COVID -19  infection
                   •  The CRISIS Study: A randomized open-label study assessing the safety and anti-coronavirus response of combined suppression of host
                       nucleotide synthesis in hospitalized adults with coronavirus-19 (COVID-19) - Purpose: Determine the safety and tolerability of SOC, SOC
                       plus brequinar, and SOC plus, brequinar plus ribavirin in hospitalized COVID-19 subjects.

                                                                         Limited Data Received
                   •  Foundation Guild of Gut Microbiota – Purpose: We will test 2 populations: COVID confirmed with diabetes   see if we help them have
                       less hospitalized days in 30 days and  Healthcare workers without covid   see if we change their microbiome and thus their rate of
                       infection
                   •  Study of Ruxolitinib in patients with COVID-19 associated cytokine storm – Purpose: Blinded, double-arm study will evaluate a
                       combination of Jakafi alongside standard-of-care therapy to treat COVID19 patients with pneumonia.
                   •  ANG-3777 to Treat Pulmonary Complications in COVID
                   •  RFA-1 for detecting the presence of COVID-19 -  Methodology: ED saliva samples (total 300 patients)
                   •  Blood Specimens and Clinical Data from Patients with PCR confirmed COVID-19 – Methodology:
                       Transmedic; home collection of blood from COVID 19 positive patients









                                                                                                                                               14
   10   11   12   13   14   15